References of "Lancet"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailGenetic determinants of Crohn’s disease and ulcerative colitis phenotypes in 34,819 patients.
Cleynen, Isabelle; Boucher, Gabrielle; Jostins, Luke et al

in Lancet (in press)

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailWhich incretin-based therapy for type 2 diabetes?
Scheen, André ULg

in Lancet (2014)

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailDisorders of consciousness: Are we ready for a paradigm shift? - Authors' reply
Jox, RJ; Bernat, JL; Laureys, Steven ULg et al

in Lancet (2013), Vol 12

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailReanalysis of “Bedside detection of awareness in the vegetative state: a cohort study”
Goldfine, Andrew; Bardin, Jonathan; Noirhomme, Quentin ULg et al

in Lancet (2013), 381

Detailed reference viewed: 160 (8 ULg)
Full Text
Peer Reviewed
See detailGliptin versus a sulphonylurea as add-on to metformin.
SCHEEN, André ULg; Paquot, Nicolas ULg

in Lancet (2012), 380

Detailed reference viewed: 38 (5 ULg)
Full Text
Peer Reviewed
See detailIntensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
Récher, Christian; Coiffier, Bertrand; Haioun, Corinne et al

in Lancet (2011), 378(9806)

Background The outcome of diff use large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. We aimed to assess, in ... [more ▼]

Background The outcome of diff use large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. We aimed to assess, in patients aged 18–59 years, the potential survival benefi t provided by a dose-intensive immunochemotherapy regimen plus rituximab compared with standard treatment plus rituximab. Methods We did an open-label randomised trial comparing dose-intensive rituximab, doxorubicin, cyclo phosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) with subsequent consolidation versus standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). Random assignment was done with a computer-assisted randomisation-allocation sequence with a block size of four. Patients were aged 18–59 years with untreated diff use large B-cell lymphoma and an age-adjusted international prognostic index equal to 1. Our primary endpoint was event-free survival. Our analyses of effi cacy and safety were of the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00140595. Findings One patient withdrew consent before treatment and 54 did not complete treatment. After a median follow-up of 44 months, our 3-year estimate of event-free survival was 81% (95% CI 75–86) in the R-ACVBP group and 67% (59–73) in the R-CHOP group (hazard ratio [HR] 0·56, 95% CI 0·38–0·83; p=0·0035). 3-year estimates of progression-free survival (87% [95% CI, 81–91] vs 73% [66–79]; HR 0·48 [0·30–0·76]; p=0·0015) and overall survival (92% [87–95] vs 84% [77–89]; HR 0·44 [0·28–0·81]; p=0·0071) were also increased in the R-ACVBP group. 82 (42%) of 196 patients in the R-ACVBP group experienced a serious adverse event compared with 28 (15%) of 183 in the R-CHOP group. Grade 3–4 haematological toxic eff ects were more common in the R-ACVBP group, with a higher proportion of patients experiencing a febrile neutropenic episode (38% [75 of 196] vs 9% [16 of 183]). Interpretation Compared with standard R-CHOP, inten sifi ed immunochemotherapy with R-ACVBP signifi cantly improves survival of patients aged 18–59 years with diff use large B-cell lymphoma with low-intermediate risk according to the International Prognostic Index. Haematological toxic eff ects of the intensive regimen were raised but manageable. Funding Groupe d’Etudes des Lymphomes de l’Adulte and Amgen. [less ▲]

Detailed reference viewed: 45 (3 ULg)
Full Text
Peer Reviewed
See detailEffects of fibrates on cardiovascular outcomes.
Delanaye, Pierre ULg; Scheen, André ULg

in Lancet (2010), 376(9746), 1051

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailRimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
Topol, E. J.; Scheen, André ULg

in Lancet (2010), 376

BACKGROUND: Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant ... [more ▼]

BACKGROUND: Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival. METHODS: This double-blind, placebo-controlled trial was undertaken in 974 hospitals in 42 countries. 18,695 patients with previously manifest or increased risk of vascular disease were randomly assigned to receive either rimonabant 20 mg (n=9381) or matching placebo (n=9314). Randomisation was stratified by centre, implemented with an independent interactive voice response system, and all study personnel and participants were masked to group assignment. The primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke, as determined via central adjudication. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00263042. FINDINGS: At a mean follow-up of 13.8 months (95% CI 13.6-14.0), the trial was prematurely discontinued because of concerns by health regulatory authorities in three countries about suicide in individuals receiving rimonabant. All randomised participants were analysed. At the close of the trial (Nov 6, 2008), the composite primary endpoint of cardiovascular death, myocardial infarction, or stroke occurred in 364 (3.9%) patients assigned to rimonabant and 375 (4.0%) assigned to placebo (hazard ratio 0.97, 95% CI 0.84-1.12, p=0.68). With rimonabant, gastrointestinal (3038 [33%] vs 2084 [22%]), neuropsychiatric (3028 [32%] vs 1989 [21%]), and serious psychiatric side-effects (232 [2.5%] vs 120 [1.3%]) were significantly increased compared with placebo. Four patients in the rimonabant group and one in the placebo group committed suicide. INTERPRETATION: The premature termination of this trial has important lessons for drug development. A drug that was being marketed for weight loss, but being tested for improving cardiovascular outcomes, induced a level of serious neuropsychiatric effects that was deemed unacceptable by regulatory authorities, and both the drug and the trial were abruptly terminated. [less ▲]

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailAddition of incretin therapy to metformin in type 2 diabetes.
Scheen, André ULg; Radermecker, Régis ULg

in Lancet (2010), 375(9724), 1410-2

Detailed reference viewed: 31 (5 ULg)
Full Text
Peer Reviewed
See detailClinical staging: a new scenario for the treatment of psychosis
Raballo, A.; Laroi, Frank ULg

in Lancet (2009), 374(9687), 365-367

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid, David M; Devogelaer, Jean-Pierre; Saag, Kenneth et al

in Lancet (2009), 373(9671), 1253-63

BACKGROUND: Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. Concurrent oral bisphosphonates increase bone mineral density and reduce frequency of vertebral ... [more ▼]

BACKGROUND: Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. Concurrent oral bisphosphonates increase bone mineral density and reduce frequency of vertebral fractures, but are associated with poor compliance and adherence. We aimed to assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis. METHODS: This 1-year randomised, double-blind, double-dummy, non-inferiority study of 54 centres in 12 European countries, Australia, Hong Kong, Israel, and the USA, tested the effectiveness of 5 mg intravenous infusion of zoledronic acid versus 5 mg oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis. 833 patients were randomised 1:1 to receive zoledronic acid (n=416) or risedronate (n=417). Patients were stratified by sex, and allocated to prevention or treatment subgroups dependent on duration of glucocorticoid use immediately preceding the study. The treatment subgroup consisted of those treated for more than 3 months (272 patients on zoledronic acid and 273 on risedronate), and the prevention subgroup of those treated for less than 3 months (144 patients on each drug). 62 patients did not complete the study because of adverse events, withdrawal of consent, loss to follow-up, death, misrandomisation, or protocol deviation. The primary endpoint was percentage change from baseline in lumbar spine bone mineral density. Drug efficacy was assessed on a modified intention-to-treat basis and safety was assessed on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00100620. FINDINGS: Zoledronic acid was non-inferior and superior to risedronate for increase of lumbar spine bone mineral density in both the treatment (least-squares mean 4.06% [SE 0.28] vs 2.71% [SE 0.28], mean difference 1.36% [95% CI 0.67-2.05], p=0.0001) and prevention (2.60% [0.45] vs 0.64% [0.46], 1.96% [1.04-2.88], p<0.0001) subgroups at 12 months. Adverse events were more frequent in patients given zoledronic acid than in those on risedronate, largely as a result of transient symptoms during the first 3 days after infusion. Serious adverse events were worsening rheumatoid arthritis for the treatment subgroup and pyrexia for the prevention subgroup. INTERPRETATION: A single 5 mg intravenous infusion of zoledronic acid is non-inferior, possibly more effective, and more acceptable to patients than is 5 mg of oral risedronate daily for prevention and treatment of bone loss that is associated with glucocorticoid use. [less ▲]

Detailed reference viewed: 315 (2 ULg)
Full Text
Peer Reviewed
See detailVoglibose for prevention of type 2 diabetes mellitus.
Scheen, André ULg

in Lancet (2009), 373(9675), 1579-80

Detailed reference viewed: 52 (1 ULg)
Full Text
Peer Reviewed
See detailAn assessment of interactions between global health initiatives and country health systems.
World Health Organization Maximizing Positive Synergies Collaborative Group; Porignon, Denis ULg

in Lancet (2009), 373(9681), 2137-69

Since 2000, the emergence of several large disease-specific global health initiatives (GHIs) has changed the way in which international donors provide assistance for public health. Some critics have ... [more ▼]

Since 2000, the emergence of several large disease-specific global health initiatives (GHIs) has changed the way in which international donors provide assistance for public health. Some critics have claimed that these initiatives burden health systems that are already fragile in countries with few resources, whereas others have asserted that weak health systems prevent progress in meeting disease-specific targets. So far, most of the evidence for this debate has been provided by speculation and anecdotes. We use a review and analysis of existing data, and 15 new studies that were submitted to WHO for the purpose of writing this Report to describe the complex nature of the interplay between country health systems and GHIs. We suggest that this Report provides the most detailed compilation of published and emerging evidence so far, and provides a basis for identification of the ways in which GHIs and health systems can interact to mutually reinforce their effects. On the basis of the findings, we make some general recommendations and identify a series of action points for international partners, governments, and other stakeholders that will help ensure that investments in GHIs and country health systems can fulfil their potential to produce comprehensive and lasting results in disease-specific work, and advance the general public health agenda. The target date for achievement of the health-related Millennium Development Goals is drawing close, and the economic downturn threatens to undermine the improvements in health outcomes that have been achieved in the past few years. If adjustments to the interactions between GHIs and country health systems will improve efficiency, equity, value for money, and outcomes in global public health, then these opportunities should not be missed. [less ▲]

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailChronic kidney disease in Taiwan.
Delanaye, Pierre ULg; Cavalier, Etienne ULg; Krzesinski, Jean-Marie ULg

in Lancet (2008), 372(9654), 19501950-1

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of the weight-loss drug rimonabant.
Despres, Jean-Pierre; Van Gaal, Luc; Pi-Sunyer, Xavier et al

in Lancet (2008), 371(9612), 555556-7

Detailed reference viewed: 30 (4 ULg)
Full Text
Peer Reviewed
See detailExenatide once weekly in type 2 diabetes.
Scheen, André ULg

in Lancet (2008), 372

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailCalcium and vitamin D for osteoporotic fracture risk
Reginster, Jean-Yves ULg

in Lancet (2007), 370(9588), 632-634

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailWhen the book is wrong
Leclercq, Philippe ULg; Betz, Romain ULg; Lambermont, Bernard ULg et al

in Lancet (2007), 369

Detailed reference viewed: 167 (14 ULg)
Full Text
Peer Reviewed
See detailEfficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Scheen, André ULg; Finer, Nick; Hollander, Priscilla et al

in Lancet (2006), 368(9548), 1660-72

BACKGROUND: Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of ... [more ▼]

BACKGROUND: Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulphonylureas. METHODS: 1047 overweight or obese type 2 diabetes patients (body-mass index 27-40 kg/m2) with a haemoglobin A1c (HbA1c) concentration of 6.5-10.0% (mean 7.3% [SD 0.9] at baseline) already on metformin or sulphonylurea monotherapy were given a mild hypocaloric diet and advice for increased physical activity, and randomly assigned placebo (n=348), 5 mg/day rimonabant (360) or 20 mg/day rimonabant (339) for 1 year. Two individuals in the 5 mg/day group did not receive double-blind treatment and were thus not included in the final analysis. The primary endpoint was weight change from baseline after 1 year of treatment. Analyses were done on an intention-to-treat basis. This trial is registered at ClinicalTrials.gov, number NCT00029848. FINDINGS: 692 patients completed the 1 year follow-up; numbers in each group after 1 year were much the same. Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: -1.4 kg [SD 3.6]; 5 mg/day: -2.3 kg [4.2], p=0.01 vs placebo; 20 mg/day: -5.3 kg [5.2], p<0.0001 vs placebo). Rimonabant was generally well tolerated. The incidence of adverse events that led to discontinuation was slightly greater in the 20 mg/day rimonabant group, mainly due to depressed mood disorders, nausea, and dizziness. INTERPRETATION: These data indicate that 20 mg/day rimonabant, in combination with diet and exercise, can produce a clinically meaningful reduction in bodyweight and improve HbA1c and a number of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulphonylureas. [less ▲]

Detailed reference viewed: 167 (3 ULg)